海思科(002653.SZ):獲得創新藥HSK39775片IND申請《受理通知書》
格隆匯12月10日丨海思科(002653.SZ)公佈,公司全資孫公司西藏海思科製藥有限公司於近日收到國家藥品監督管理局下發的《受理通知書》,HSK39775是我公司自主研發的一個全新的具有獨立知識產權的治療晚期實體瘤的藥物,有潛力用於治療同源重組修復缺失相關癌症,尤其是與BRCA突變相關的癌症,如乳腺癌、卵巢癌及前列腺癌。根據國家藥品監督管理局關於發佈《化學藥品註冊分類及申報資料要求》的通吿(2020年第44號)中化學藥品註冊分類的規定,本品屬於化學藥品1類。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.